Drawing on the findings of the Business Ethics for APEC SMEs Initiative, Thomas Cueni of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) outlines the benefits for small and medium-sized enterprises (SMEs) of adopting ethical practices. Cueni highlights some…
PPC China’s Sophia Duan, writing in the January edition of DIA’s Global Forum magazine, details how the emergence of an effective pharmacovigilance ecosystem is helping to safeguard the rollout of…
Writing in the January edition of DIA’s Global Forum magazine, Julia Chan, David Liew, Jana Stojanova, and Chris McMaster of Austin Health, Melbourne and St. Vincent’s Hospital Sydney outline how…
Bernie Zeiher, chief medical officer (CMO) of Astellas explains why the ‘patient-defined value’ of medicines is crucial to developing therapies that truly address patients’ unmet medical needs. Zeiher outlines some…
Thomas B. Cueni is Director General of IFPMA (www.ifpma.org), the association representing the research-based pharmaceutical companies and associations across the globe. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community find solutions that improve global health. He is also chair of the AMR Industry Alliance (www.amrindustryalliance.org) and Industry…
DIA is a global association that mobilizes life science professionals from across all areas of expertise to engage with patients, peers and thought leaders in a neutral environment on the…
Dan Leonard of the Association for Accessible Medicines (AAM) highlights five key takeaways from the organisation’s remote but dynamic annual conference, and how the US generics and biosimilars industry might…
Digital marketing expert Buck Dossey expounds the importance of soliciting user data to improve patient experiences and the ways in which AI can be utilised within this process. Companies…
Writing in the June edition of DIA’s Global Forum magazine, representatives of Japanese pharmaceutical companies with US operations outline how the COVID-19 pandemic affected their ongoing clinical studies. The…
Anthony Harrington of global investment banking and asset management firm Alantra outlines why healthcare and consulting communications companies are increasingly attractive targets for private equity. The supply of PE…
Mohamed Nasser, Amgen’s general manager for the vast Middle East & Africa (MEA) region, leverages his considerable experience managing teams across the region to highlight four skills (and one secret…
Brendan Shaw* outlines the benefits that greater adoption of outcome-based payment models for medicines can bring, highlights recent successful implementations, and explains why policy updates are so important to ensuring…
It has been a robust first half in 2018 within the life sciences sector for mergers and acquisition (M&A) and investment activities. Deal-tracking sources demonstrate M&A values witnessed meaningful increases…
Aditya Bhattacharji manages Eurasia Group‘s healthcare analysis. He calls for healthcare to be given a new prescription. But, will the private sector write it? The UK’s National Health Service has crippling…
Pierre Meulien of the Innovative Medicines Initiative (IMI) highlights why cell and gene therapies seem finally braced for mainstream adoption as well as the significant barriers that still need to…
See our Cookie Privacy Policy Here